1. Hoellen F, Griesinger G, Bohlmann MK. Therapeutic drugs in the treatment of symptomatic uterine fibroids. Expert Opin Pharmacother. 2013; 14:2079–2085.
Article
2. Pontis A, D’Alterio MN, Pirarba S, de Angelis C, Tinelli R, Angioni S. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol. 2016; 32:696–700.
Article
3. Gatti J, Brinker A, Avigan M. Spontaneous reports of seizure in association with leuprolide (lupron depot), goserelin (zoladex implant), and naferelin (synarel nasal spray). Obstet Gynecol. 2013; 121:1107.
Article
4. Pierce EJ. Angina pectoris and myocardial infarction with the use of leuprolide acetate. Am J Obstet Gynecol. 1995; 172:1323.
5. Lee SJ. Posterior reversible encephalopathy syndrome. J Korean Neurol Assoc. 2016; 34:277–289.
Article
6. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015; 14:914–925.
Article
7. Hayashi S, Kurabayashi T, Gibo J, Mizuno Y, Okamoto K. Acutely developed reversible posterior leukoencephalopathy syndrome following a prompt physical activity to avoid a traffic accident: a case report. Rinsho Shinkeigaku. 2009; 49:566–570.
Article
8. Lee CY, Hwang SH, Hong SS, Jung S, Minn YK, Kwon SB. A case of leuprolide-induced posterior reversible encephalopathy syndrome. J Neurocrit Care. 2016; 9:174–177.
Article
9. Chakrabarti S, Morton JS, Davidge ST. Mechanisms of estrogen effects on the endothelium: an overview. Can J Cardiol. 2014; 30:705–712.
Article
10. Baethmann A, Maier-Hauff K, Kempski O, Unterberg A, Wahl M, Schürer L. Mediators of brain edema and secondary brain damage. Crit Care Med. 1988; 16:972–978.
Article
11. Schots R, Kaufman L, Van Riet I, Ben Othman T, De Waele M, Van Camp B, et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia. 2003; 17:1150–1156.
Article
12. Narushima I, Kita T, Kubo K, Yonetani Y, Momochi C, Yoshikawa I, et al. Highly enhanced permeability of blood-brain barrier induced by repeated administration of endothelin-1 in dogs and rats. Pharmacol Toxicol. 2003; 92:21–26.
Article
13. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008; 29:1043–1049.
Article
14. Burnett MM, Hess CP, Roberts JP, Bass NM, Douglas VC, Josephson SA. Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors. Clin Neurol Neurosurg. 2010; 112:886–891.
Article